Related references
Note: Only part of the references are listed.Mechanisms of diabetes mellitus-induced bone fragility
Nicola Napoli et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway
Nagesha Guthalu Kondegowda et al.
CELL METABOLISM (2015)
A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women
Elena Passeri et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2015)
Differing effects of denosumab and alendronate on cortical and trabecular bone
Roger M. Zebaze et al.
BONE (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Pathogenesis of Prediabetes: Role of the Liver in Isolated Fasting Hyperglycemia and Combined Fasting and Postprandial Hyperglycemia
Rita Basu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus
Stefan Kiechl et al.
NATURE MEDICINE (2013)
Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study)
Anne L. Schafer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
PJ Kostenuik
CURRENT OPINION IN PHARMACOLOGY (2005)
Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis
R Basu et al.
DIABETES (2005)
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
DS Cai et al.
NATURE MEDICINE (2005)
Share Paper
